To Gene Voss:
Do you have the patent for the ED gel being developed by Machrochem as well as the VVUS intra-urethral patent?
Also, is the HVSF intra-urethral product a violation of your patent, or has that yet to be determined? I am looking at as many ED solution companies as I can as I feel the potential for profit will skyrocket!
<<< potence ointment
Inventors: Voss; Gene (213 Alcade Moreno, San Antonio, TX 78232); Eichler; Allen C. (1347 Lockhill-Selma, San Antonio, TX 78213). Appl. No.: 20,544Filed: Mar. 2,1987Intl. Cl. : A61K 31/47, A61K 31/50Current U.S. Cl.: 514/248; 514/307;514/400; 514/502; 514/649; 514/947Field of Search: 514/307, 400, 248, 502, 649 ----------------------------------------------------------------------
U.S. Patent Documents
1,176,597Mar., 1916Pictet2,561,071Jul., 1951Prisk128/2603,795,675Mar.,
1974Laguzzi260/2833,966,724Jun., 1976Hughes et al.260/2474,018,927Apr.,1977Vorhees514/3074,055,648Oct., 1977Sache424/2604,117,841Oct.,1978Perrotta et al.128/1554,311,707Jan., 1982Birnbaum et al.514/5304,564,010Jan., 1986Coughlan et al.128/156
Primary Examiner: Schenkman; Leonard
Attorney, Agent or Firm: Gunn, Lee & Jackson
Abstract
An ointment for relieving impotence. The ointment generally consists of a primary agent, a carrier, and a base, and is applied directly to the penis. The primary agent is a vasodilator selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine. The carrier is used to assist absorption of the primary agent through the skin around the penis. When the primary agent enters the corpora cavernosa within the penis, it causes dilation of the corpora, resulting in an erection. >>> |
